Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, ...
As per Future Market Insights, PSG devices are expected to be the most preferred sleep apnea diagnostic systems during the ...
ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...
The American Heart Association says heart diseases are the leading cause of death in the US. Experts tell Digital Trends that ...
ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...
Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...
The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030.
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...
According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...
You can do better than sleeping pills or counting sheep. From free apps and wearable trackers to smart mattresses and climate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results